| Author | Mitchell, Kate M. | |
| Author | Boily, Marie-Claude | |
| Author | Hanscom, Brett | |
| Author | Moore, Mia | |
| Author | Todd, Jeffery | |
| Author | Paz-Bailey, Gabriela | |
| Author | Wejnert, Cyprian | |
| Author | Liu, Albert | |
| Author | Donnell, Deborah J. | |
| Author | Grinsztejn, Beatriz | |
| Author | Landovitz, Raphael J. | |
| Author | Dimitrov, Dobromir T. | |
| Access date | 2023-05-15T23:42:36Z | |
| Available date | 2023-05-15T23:42:36Z | |
| Document date | 2023 | |
| Citation | MITCHELL, Kate M. et al. Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083. Lancet Regional Health. Americas, v. 18, p. 1-13, Jan. 2023. | en_US |
| ISSN | 2667-193X | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/58410 | |
| Sponsorship | NIH, MRC. | en_US |
| Language | eng | en_US |
| Publisher | Elsevier | en_US |
| Rights | open access | en_US |
| Title | Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083 | en_US |
| Type | Article | en_US |
| DOI | 10.1016/j.lana.2022.100416 | |
| Abstract | Background: The HPTN 083 trial demonstrated superiority of HIV pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB) to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) among men who have sex with men (MSM). We compared the potential population-level impact of TDF/FTC and CAB among MSM in Atlanta, Georgia. Methods: An MSM HIV transmission model was calibrated to Atlanta-specific data on HIV prevalence and PrEP usage (percentage of uninfected MSM on PrEP), assuming only PrEP-indicated MSM used PrEP. CAB effectiveness (efficacy × adherence) of 91% was estimated using data from HPTN 083 and previous TDF/FTC trials. We estimated HIV infections averted over 5/10 years if TDF/FTC use were maintained, or if all TDF/FTC users switched to CAB in January 2022 (vs. no PrEP or continued TDF/FTC use). CAB scenarios with 10%/20% more users were also considered. Progress towards Ending the HIV Epidemic (EHE) goals (75%/90% fewer HIV infections in 2025/2030 vs. 2017) was estimated. Findings: We predicted TDF/FTC at current usage (∼28%) would avert 36.3% of new HIV infections (95% credible interval 25.6-48.7%) among all Atlanta MSM over 2022-2026 vs. no PrEP. Switching to CAB with similar usage may prevent 44.6% (33.2-56.6%) infections vs. no PrEP and 11.9% (5.2-20.2%) infections vs. continued TDF/FTC. Increasing CAB usage 20% could increase the incremental impact over TDF/FTC to 30.0% over 2022-2026, getting ∼60% towards reaching EHE goals (47%/54% fewer infections in 2025/2030). Reaching the 2030 EHE goal would require 93% CAB usage. Interpretation: If CAB effectiveness were like HPTN 083, CAB could prevent more infections than TDF/FTC at similar usage. Increased CAB usage could contribute substantially towards reaching EHE goals, but the usage required to meet EHE goals is unrealistic. | en_US |
| Affilliation | MRC Centre for Global Infectious Disease Analysis. School of Public Health. Imperial College London. London, United Kingdom / HIV Prevention Trials Network Modelling Centre. Imperial College London. London, United Kingdom. | en_US |
| Affilliation | MRC Centre for Global Infectious Disease Analysis. School of Public Health. Imperial College London. London, United Kingdom / HIV Prevention Trials Network Modelling Centre. Imperial College London. London, United Kingdom. | en_US |
| Affilliation | Vaccine and Infectious Disease Division. Fred Hutchinson Cancer Center. Seattle, WA, USA. | en_US |
| Affilliation | Vaccine and Infectious Disease Division. Fred Hutchinson Cancer Center. Seattle, WA, USA. | en_US |
| Affilliation | Centers for Disease Control and Prevention. Atlanta, GA, USA. | en_US |
| Affilliation | Division of Vector-Borne Diseases. Centers for Disease Control and Prevention. San Juan, Puerto Rico. | en_US |
| Affilliation | Centers for Disease Control and Prevention. Atlanta, GA, USA. | en_US |
| Affilliation | Bridge HIV, Population Health Division. San Francisco Department of Public Health. San Francisco, CA, USA / University of California San Francisco. Department of Medicine. San Francisco, CA, USA. | en_US |
| Affilliation | Vaccine and Infectious Disease Division. Fred Hutchinson Cancer Center. Seattle, WA, USA. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | University of California Los Angeles. Center for Clinical AIDS Research and Education. Los Angeles, CA, USA / Division of Infectious Diseases. David Geffen School of Medicine at UCLA. Los Angeles, CA, USA. | en_US |
| Affilliation | accine and Infectious Disease Division. Fred Hutchinson Cancer Center. Seattle, WA, USA. | en_US |
| Subject | Cabotegravir | en_US |
| Subject | HIV | en_US |
| Subject | Injectable PrEP | en_US |
| Subject | Long-acting PrEP | en_US |
| Subject | MSM | en_US |
| Subject | Mathematical modelling | en_US |
| Subject | Men who have sex with men | en_US |
| Subject | Pre-exposure prophylaxis | en_US |
| e-ISSN | 2667-193X | |
| xmlui.metadata.dc.subject.ods | 05 Igualdade de gênero | |
